Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

290
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
290

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111.

Blood vessels, thrombosis & hemostasis·2026
Same author

Hyperacute Interleukin-1β Production and Neutrophil Extracellular Trap Formation in the Cerebral Circulation of Stroke Patients with Large Vessel Occlusion.

Annals of neurology·2026
Same author

Circulating biomarkers improve prediction of postoperative outcome after aortic valve surgery.

Frontiers in cardiovascular medicine·2026
Same author

Extracellular traps from myeloid cells as therapeutic targets in traumatic heterotopic ossification.

Science translational medicine·2026
Same author

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition.

International journal of cancer·2026
Same author

Linking rare variants to cell-type function in profound autism with brain transcriptomics and foundation models.

Cell genomics·2026

Related Experiment Video

Updated: Feb 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Novel targets for anticoagulants lacking bleeding risk.

Julia K Bickmann1, Trevor Baglin, Joost C M Meijers

  • 1aInstitute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany bDepartment of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK cDepartment of Plasma Proteins, Sanquin Research, Plesmanlaan dDepartment of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands eDepartment of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden.

Current Opinion in Hematology
|July 22, 2017
PubMed
Summary

Novel anticoagulants targeting specific coagulation factors offer a promising approach to prevent dangerous blood clots without increasing bleeding risk. This research explores new ways to treat thrombosis safely.

More Related Videos

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.8K

Related Experiment Videos

Last Updated: Feb 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.8K

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Thromboembolic diseases pose a significant health burden, necessitating effective anticoagulation.
  • Current anticoagulants (heparins, vitamin K antagonists, direct inhibitors) carry a high risk of bleeding due to targeting essential fibrin-forming enzymes.
  • Fibrin is crucial for both pathological thrombosis and essential hemostasis, creating a therapeutic challenge.

Purpose of the Study:

  • To review recent advancements in targeting coagulation proteins for safer anticoagulation.
  • To explore novel therapeutic strategies that differentiate between thrombosis and hemostasis.
  • To identify potential new anticoagulant drugs with reduced bleeding complications.

Main Methods:

  • Review of experimental and preclinical data on coagulation mechanisms.
  • Analysis of studies focusing on selective targeting of coagulation factors.
  • Examination of the differential roles of coagulation proteins in thrombosis versus hemostasis.

Main Results:

  • Emerging evidence suggests distinct coagulation pathways for thrombosis and hemostasis.
  • Coagulation factors XI and XII play differential roles, presenting therapeutic targets.
  • Targeting these specific factors may allow for anticoagulation with a reduced risk of hemorrhage.

Conclusions:

  • Selective targeting of coagulation proteins offers a potential breakthrough in anticoagulant therapy.
  • Novel approaches aim to interfere with pathological thrombosis without compromising hemostasis.
  • This strategy could lead to a new generation of safer anticoagulant medications.